• Zydus, XOMA Enter IO Agreement contractpharma
    March 10, 2020
    To advance an IL-2-based immuno-oncology drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody.
PharmaSources Customer Service